Key result
Atorvastatin suppresses high-TRIB1 pancreatic cancer growth by targeting upregulated cholesterol biosynthesis.
TRIB1 drives metabolic rewiring in PDAC by promoting cholesterol biosynthesis via the PPARγ-HMGCR axis, suggesting it could serve as a biomarker for statin sensitivity in pancreatic cancer.
Metabolic reprogramming, particularly the dysregulation of cholesterol metabolism, is a hallmark of pancreatic ductal adenocarcinoma (PDAC). However, the underlying molecular drivers remain largely elusive. In this study, we demonstrate that Tribbles homolog 1 (TRIB1) is elevated in PDAC tissues and is significantly associated with poor prognosis. Functionally, TRIB1 mRNA knockdown suppresses PDAC cell growth and tumor formation, while its overexpression promotes both. Mechanistically, TRIB1 protein binds to the DNA-binding domain of PPARγ and inhibits its transcriptional activity. This interaction relieves the PPARγ-mediated repression of HMGCR, the rate-limiting enzyme in the mevalonate pathway, thereby fueling de novo cholesterol biosynthesis. Furthermore, in vivo experiments indicate that PDAC tumors with high TRIB1 expression were more sensitive to the HMGCR inhibitor atorvastatin. Collectively, our findings highlight the critical role of the TRIB1-PPARγ-HMGCR axis in the metabolic rewiring of PDAC and suggest that TRIB1 may serve as a predictive biomarker for optimizing statin-based metabolic therapies.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied Pancreatic ductal adenocarcinoma (PDAC). TRIB1 knockdown/overexpression and atorvastatin was evaluated. TRIB1 promotes pancreatic ductal adenocarcinoma growth by inhibiting PPARγ and upregulating cholesterol biosynthesis, making high-TRIB1 tumors more sensitive to atorvastatin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: